Advanced Melanoma Clinical Trial Pipeline Analysis Demonstrates 55+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight New York, USA, July 08, 2024 (GLOBE NEWSWIRE) -- Advanced Melanoma Clinical Trial Pipeline Analysis Demonstrates 55+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm,...

Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today...